Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Cereno Scientific AB Series B
CRNO-BCereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System, as well as collaboration with the Pulmonary and Vascular Research Institute (PVRI). Cereno Scientific AB (publ) was founded in 2012 and is headquartered in Gothenburg, Sweden. Address: BioVentureHub, Gothenburg, Sweden, 431 83
Analytics
Precio Objetivo de WallStreet
144.55 SEKRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave CRNO-B
Análisis de dividendos CRNO-B
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout CRNO-B
Valoración de la acción CRNO-B
Finanzas CRNO-B
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |